Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Major Shareholder Perceptive Advisors Llc Acquires 8,374 Shares

Aldeyra Therapeutics, Inc (NASDAQ:ALDXGet Free Report) major shareholder Perceptive Advisors Llc bought 8,374 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was purchased at an average price of $3.25 per share, with a total value of $27,215.50. Following the completion of the acquisition, the insider now owns 8,601,960 shares of the company’s stock, valued at $27,956,370. The purchase was disclosed in a filing with the SEC, which is available through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Perceptive Advisors Llc also recently made the following trade(s):

  • On Wednesday, April 3rd, Perceptive Advisors Llc purchased 309,847 shares of Aldeyra Therapeutics stock. The shares were bought at an average price of $4.09 per share, with a total value of $1,267,274.23.

Aldeyra Therapeutics Stock Performance

Shares of ALDX opened at $4.15 on Thursday. The firm has a market cap of $244.44 million, a PE ratio of -6.48 and a beta of 1.51. The firm’s 50 day moving average price is $3.34 and its 200 day moving average price is $3.42. Aldeyra Therapeutics, Inc has a twelve month low of $1.42 and a twelve month high of $11.97.

Aldeyra Therapeutics (NASDAQ:ALDXGet Free Report) last released its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.13. On average, sell-side analysts anticipate that Aldeyra Therapeutics, Inc will post -0.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aldeyra Therapeutics

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Aldeyra Therapeutics by 23.2% in the fourth quarter. Vanguard Group Inc. now owns 3,927,597 shares of the biotechnology company’s stock valued at $13,786,000 after purchasing an additional 740,177 shares during the period. BlackRock Inc. increased its position in Aldeyra Therapeutics by 228.0% during the second quarter. BlackRock Inc. now owns 3,230,414 shares of the biotechnology company’s stock worth $27,103,000 after acquiring an additional 2,245,432 shares during the period. State Street Corp increased its position in Aldeyra Therapeutics by 1,655.5% during the second quarter. State Street Corp now owns 3,041,866 shares of the biotechnology company’s stock worth $25,521,000 after acquiring an additional 2,868,585 shares during the period. Knoll Capital Management LLC increased its position in Aldeyra Therapeutics by 45.9% during the second quarter. Knoll Capital Management LLC now owns 3,015,668 shares of the biotechnology company’s stock worth $25,301,000 after acquiring an additional 948,508 shares during the period. Finally, Verition Fund Management LLC increased its position in Aldeyra Therapeutics by 54.1% during the first quarter. Verition Fund Management LLC now owns 2,105,907 shares of the biotechnology company’s stock worth $9,361,000 after acquiring an additional 739,206 shares during the period. Institutional investors own 59.71% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on ALDX. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a report on Tuesday. StockNews.com raised shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, January 29th. Finally, Oppenheimer raised shares of Aldeyra Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price objective on the stock in a research report on Wednesday.

Check Out Our Latest Research Report on Aldeyra Therapeutics

About Aldeyra Therapeutics

(Get Free Report)

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.

See Also

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.